Jeff Hansen

Jeff Hansen

| This email address is being protected from spambots. You need JavaScript enabled to view it.

Research Editor

jeffhans@uab.edu | (205) 209-2355

Communicates UAB research discoveries and initiatives from across the university for a variety of audiences.

Specific beats: 

  • Alabama Drug Discovery Alliance
  • Biochemistry and Molecular Genetics 
  • Biomatrix Engineering and Regenerative Medicine 
  • Cell biology 
  • Center for Biophysical Sciences and Engineering 
  • CCTS
  • Center for Metabolic Bone Disease 
  • Microbiology 
  • Neurobiology 
  • Comprehensive Neuroscience Center 
  • Pathology, research shared with MS2
  • Pharmacology and Toxicology 
  • Physiology and Biophysics 
  • UAB Research Foundation/IIE 
  • Research Administration
Description of this mechanism offers a promising therapeutic target to limit lung injury and death. Lower respiratory tract infections, including bacterial pneumonia, are the fourth-leading cause of death worldwide, with 120 million to 156 million cases and 1.4 million deaths a year.
This is the first example of a chelator-free-radiolabeled polymersome capable of a long-term multiday positron emission tomography, or PET, imaging study in vivo.
Researchers identify a new target to fight infections caused by the opportunistic lung pathogen Streptococcus pneumoniae — interference with the bacteria’s fermentation metabolism.
These effector memory B cells appear poised for a rapid serum antibody response upon secondary challenge one year later, and evidence shows that the cells in this subset differ from all previously described memory B cell subsets.
The grant validates the science of Alveolus Bio, and the funds will support development of first-of-its-kind inhaled biotherapeutics to treat chronic lung diseases.
The federal mandate, which was announced in 2011 and implemented in 2014, limited acetaminophen to 325 milligrams per opioid-acetaminophen combination pill. Acetaminophen is toxic to livers at high doses.
Mechanistic findings in this study may pave the way for future time-restricted feeding studies in muscle, providing a natural and affordable form of alternative therapy for managing pathologies related to metabolism and obesity.
Having a bacterial infection at the same time as COVID-19 is a greater risk factor for COVID-19 severity and mortality than previously described risk factors such as advanced age, male sex or various comorbidities.
The clinical trial focused on very young children, who have a more rapid loss of the pancreatic beta cells than do adolescents. The trial was constrained to a low-dose level, but showed safety and tolerability and reduced serum glucagon, a secondary outcome.
Basic research in bacteria has led Michael Niederweis and Moon Nahm to 17 U.S. patents and various new technologies with real impacts on the welfare of society.
Page 6 of 51